Hospital-Acquired Pneumonia Market Intelligence: Size, Share and Growth Outlook Through 2036
By Drug Class, Infection Type, Route of Administration, End User — Global Forecast to 2036
By Brevintel Editor•August 2026•PDF + Excel
Market Size (2026)
$8.4B
Market Forecast (2036)
$14.8B
CAGR (2026-2036)
5.8%
Sales in hospital-acquired pneumonia market are projected to rise from USD 8.4 billion in 2026 to USD 14.8 billion by 2036 at a 5.8% CAGR. Treatment demand continues to be shaped by drug-resistant Gram-negative pathogens that remain a priority for hospital infection control programs. The WHO's May 2024 bacterial priority pathogens list retained carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, underscoring the need for effective antimicrobial therapies against hospital-acquired infections. The persistence of resistant pathogens continues to influence antibiotic development and prescribing strategies.
Key Market Trends & Insights
Sales in hospital-acquired pneumonia market are projected to rise from USD 8.4 billion in 2026 to USD 14.8 billion by 2036 at a 5.8% CAGR.
The WHO's May 2024 bacterial priority pathogens list retained carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, underscoring the need for effective antimicrobial therapies against hospital-acquired infections.
USD 8.4 billion in 2026 and USD 14.8 billion by 2036 at a 5.8% CAGR.
Treatment demand continues to be shaped by drug-resistant Gram-negative pathogens that remain a priority for hospital infection control programs.
Japan is forecast to expand at a 5.9% CAGR compared with 5.4% for the United States.
CDC reported in January 2026 that ventilator-associated events declined by 2% during 2024.
Resistant pathogens sustain demand, stewardship limits unrestricted use and faster diagnostics support better treatment matching.
Market Overview
Overview
USD 8.4 billion in 2026 and USD 14.8 billion by 2036 at a 5.8% CAGR.
Market Dynamics
Overview
Resistant pathogens sustain demand, stewardship limits unrestricted use and faster diagnostics support better treatment matching.
Segmentation Analysis
Segment Overview
The Hospital-Acquired Pneumonia Market is segmented by drug class, infection type, route of administration, end user, distribution channel and region.
Drug class covers antibiotics, combination therapy, adjunctive therapies and pipeline therapies, while infection type includes ventilator-associated, non-ventilator and drug-resistant pneumonia.
Routes include injectable, oral and inhaled therapy, while hospitals, respiratory centers and long-term care facilities obtain medicines through hospital, retail and online pharmacies.
Why do antibiotics lead demand within the drug class category?
Clinicians start antibiotic drugs for severe inpatient pneumonia before complete susceptibility results become available, then culture review narrows coverage according to organism risk and clinical response.
By drug class, antibiotics are estimated to hold 64.0% in 2026 owing to their direct role in suspected bacterial infection.
Combination regimens extend empiric coverage or inhibit beta-lactamases, whereas adjunctive and pipeline approaches supplement treatment without replacing active antibacterial therapy.
Why does ventilator-associated pneumonia lead the infection type category?
Ventilator-associated pneumonia follows critical-care drug pathways combining respiratory support and microbiology review, while device-specific surveillance concentrates diagnosis and treatment inside intensive care units.
In 2026, ventilator-associated pneumonia is expected to lead infection type with 56.0% share because ventilated patients require intensive monitoring and treatment.
Non-ventilator disease spans surgical and general wards, whereas resistant cases require organism-specific selection for MRSA, Pseudomonas aeruginosa or Acinetobacter baumannii.
Why do injectable therapies lead the route of administration category?
Regional Outlook
Regional Overview
The country forecasts span 0.9 percentage point between Japan and Germany, but similar rates mask different surveillance, prescribing and access conditions.
Japan’s pace reflects extensive inpatient susceptibility surveillance that informs empiric protocols and hospital formulary review.
The United Kingdom combines national treatment guidance with monitored secondary-care antibiotic use and mandatory intravenous review.
The United States combines resistant-pathogen approvals with prevention programs that reduce selected device-associated infection events.
France links hospital antibiotic surveillance with stronger review of broad-spectrum prescribing and resistance patterns.
Germany relies on national reference laboratories and strict prescribing controls for multidrug-resistant Gram-negative infections.
Comparable CAGRs reflect surveillance and stewardship differences across North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa.
Country-wise Analysis
Japan is projected to expand at a 5.9% CAGR through 2036 as surveillance data remain closely integrated with hospital prescribing decisions.
JANIS supplies participating hospitals with antimicrobial susceptibility information that supports empiric treatment selection.
JANIS recorded 8.75 million inpatient specimens from 2,958 facilities during 2024.
The dataset helps clinicians align therapy with local resistance patterns.
Competitive Landscape
Overview
Merck & Co., Inc., Pfizer Inc., Shionogi & Co., Ltd., Innoviva Specialty Therapeutics, Inc., Basilea Pharmaceutica Ltd., ADVANZ PHARMA Holdco Limited, Allecra Therapeutics GmbH and A. Menarini Industrie Farmaceutiche Riunite S.r.l. are the notable companies included in this market assessment.
Key Companies Covered
Merck & Co., Inc.
Pfizer Inc.
Shionogi & Co., Ltd.
Innoviva Specialty Therapeutics, Inc.
Basilea Pharmaceutica Ltd.
ADVANZ PHARMA Holdco Limited
Allecra Therapeutics GmbH
A. Menarini Industrie Farmaceutiche Riunite S.r.l.
Table of Contents
The complete report includes additional chapters, data tables, and company profiles beyond this preview.
Key Takeaways
Market Size and CAGR
Top Growth Driver
Fastest Growing Segment
Leading Region
Key Companies
Emerging Opportunities
Executive Summary
Global Market Outlook
Demand-side Trends
Supply-side Trends
Technology Roadmap Analysis
Analysis and Recommendations
Analyst Perspective (What is happening? Why now? What should investors know?)
